
Quarterly report 2025-Q3
added 11-06-2025
Nephros Financial Ratios 2011-2026 | NEPH
Annual Financial Ratios Nephros
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-14.3 | -1.5 | -11.7 | -15.3 | -20.8 | -10.7 | -30.8 | -7.7 | -3.9 | -2.3 | -1.7 | -4.8 | -3.2 |
P/S |
1.6 | 1.1 | 4.4 | 8.5 | 6.9 | 6.4 | 6.5 | 10.1 | 6.3 | 9.7 | 3.6 | 8.7 | 3.4 |
EPS |
-0.1 | -0.7 | -0.4 | -0.5 | -0.5 | -0.5 | -0.0 | -0.1 | -0.1 | -0.3 | 0.1 | -0.6 | -0.8 |
EV (Enterprise Value) |
21.7 M | 9.4 M | 41.3 M | 67.5 M | 75.2 M | 35.5 M | 25.7 M | 25.1 M | 12.2 M | 24.7 M | 9.17 M | 19.8 M | 8.51 M |
EBITDA per Share |
-0.13 | -0.4 | -0.31 | -0.477 | -0.394 | -0.417 | -0.341 | -0.489 | -0.83 | -0.927 | -1.78 | -2.55 | -2.31 |
EV/EBITDA |
-8.7 | -15.2 | -23.1 | -11.8 | -12.1 | -9.0 | -3.4 | -6.4 | -2.3 | -4.9 | -2.7 | ||
PEG |
1.24 | -0.24 | 2.14 | 0.38 | -1.25 | 0.05 | -0.46 | -0.23 | -0.06 | 0.08 | -0.1 | 0.65 | -0.05 |
P/B |
2.7 | 1.2 | 3.1 | 5.8 | 15.2 | 9.6 | 12.8 | 35.0 | 4.6 | -3.0 | -10.2 | -26.4 | 5.4 |
P/CF |
27.3 | -3.4 | -32.0 | -10.2 | -31.1 | -9.9 | -323.1 | -10.8 | -3.2 | -6.8 | -1.7 | -7.1 | -5.9 |
ROE % |
-18.84 | -127.07 | -33.07 | -38.06 | -73.16 | -89.57 | -41.49 | -454.57 | -115.92 | 129.75 | 606.23 | 548.24 | -166.08 |
ROA % |
-13.28 | -64.61 | -21.91 | -25.75 | -29.41 | -32.22 | -16.24 | -113.22 | -77.78 | -218.79 | -128.00 | -92.46 | -59.09 |
ROCE % |
-19.06 | -77.52 | -27.81 | -26.21 | -34.29 | -38.16 | -71.53 | -160.91 | -113.62 | -125.78 | 543.77 | -2975.89 | -162.56 |
Current Ratio |
3.4 | 5.2 | 6.1 | 11.4 | 3.4 | 3.1 | 2.0 | 1.4 | 2.6 | 1.4 | 0.3 | 0.4 | 1.2 |
DSO |
35.7 | 53.6 | 53.7 | 58.2 | 36.9 | 93.2 | 80.1 | 61.0 | 74.5 | 23.0 | 25.6 | 188.9 | 192.9 |
DIO |
175.9 | 265.0 | 388.8 | 530.7 | 220.0 | 273.9 | 162.2 | 170.4 | 244.0 | 123.7 | 65.8 | 154.5 | 67.0 |
DPO |
50.5 | 72.2 | 70.0 | 42.3 | 82.4 | 122.8 | 209.8 | 208.1 | 269.2 | 555.1 | 436.1 | 1182.7 | 77.0 |
Operating Cycle |
211.6 | 318.6 | 442.5 | 588.8 | 256.9 | 367.1 | 242.3 | 231.4 | 318.6 | 146.6 | 91.4 | 343.4 | 259.9 |
Cash Conversion Cycle |
161.1 | 246.4 | 372.5 | 546.5 | 174.6 | 244.2 | 32.5 | 23.3 | 49.4 | -408.5 | -344.7 | -839.3 | 182.9 |
All numbers in USD currency
Quarterly Financial Ratios Nephros
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
0.03 | 0.02 | 0.05 | - | 0.02 | -0.03 | -0.02 | - | -0.02 | -0.04 | -0.03 | - | -0.31 | -0.12 | -0.2 | - | -0.12 | -0.12 | -0.06 | - | -0.12 | -0.19 | -0.13 | - | -0.1 | -0.14 | -0.2 | - | -0.08 | -0.1 | -0.03 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.02 | -0.02 | - | -0.02 | -0.06 | 0.01 | - | 0.11 | -0.21 | -0.19 | - | -0.14 | -0.1 | 0.13 | - | -0.07 | -0.07 | -0.05 | - | -0.04 | -0.06 | -0.18 |
EBITDA per Share |
0.03 | 0.03 | 0.06 | - | 0.02 | -0.03 | -0.02 | - | -0.01 | -0.04 | -0.02 | - | -0.12 | -0.07 | -0.15 | - | -0.07 | -0.11 | -0.1 | - | -0.1 | -0.17 | -0.11 | - | -0.08 | -0.11 | -0.18 | - | -0.07 | -0.09 | -0.02 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | -0.02 | -0.02 | - | -0.03 | -0.02 | -0.02 | - | -0.02 | -0.02 | -0.03 | - | -0.03 | -0.04 | -0.08 | - | -0.07 | -0.07 | -0.05 | - | -0.04 | -0.06 | -0.06 |
ROE % |
14.08 | 12.95 | 6.84 | -3.47 | -5.58 | -9.93 | -11.29 | -10.55 | -43.47 | -74.28 | -78.39 | -56.71 | -64.68 | -39.73 | -38.13 | -18.94 | -27.02 | -27.13 | -32.85 | -30.08 | -46.00 | -53.83 | -60.75 | -64.92 | -79.82 | -78.81 | -76.62 | -70.48 | -102.89 | -120.40 | -142.75 | -107.59 | -213.44 | -286.87 | -371.75 | -356.37 | -378.18 | -294.14 | -237.09 | -80.82 | -128.75 | -154.87 | 7.24 | 107.85 | 502.60 | 945.29 | 1060.98 | 356.23 | 499.59 | 248.20 | 165.25 | 363.70 | 334.63 | 162.21 | -6.88 | -121.18 | -29.06 | -42.36 | -49.75 |
ROA % |
10.98 | 10.20 | 5.66 | -2.32 | -3.99 | -7.42 | -8.98 | -8.64 | -36.46 | -62.62 | -66.05 | -48.10 | -54.95 | -33.99 | -32.64 | -16.11 | -21.58 | -20.19 | -22.88 | -20.35 | -26.75 | -27.68 | -26.83 | -26.10 | -31.46 | -30.42 | -28.78 | -25.36 | -38.04 | -45.36 | -54.67 | -42.10 | -68.47 | -82.15 | -97.55 | -88.76 | -103.40 | -91.67 | -106.20 | -54.23 | 26.59 | 122.05 | 9.30 | -181.86 | -265.21 | -429.39 | -315.19 | -75.22 | -99.39 | -40.22 | -17.32 | -61.34 | -71.68 | -57.84 | -51.54 | -43.11 | -10.34 | -15.07 | -17.70 |
ROCE % |
14.33 | 13.72 | 7.13 | -3.92 | -6.28 | -11.15 | -12.18 | -10.82 | -24.19 | -35.21 | -36.70 | -31.44 | -36.67 | -28.53 | -29.46 | -19.23 | -26.68 | -28.89 | -34.20 | -28.40 | -43.26 | -50.69 | -56.49 | -61.26 | -74.72 | -73.30 | -71.93 | -60.22 | -86.78 | -99.89 | -118.59 | -93.49 | -188.99 | -257.93 | -344.52 | -338.83 | -379.63 | -324.93 | -224.74 | -93.36 | -81.37 | -28.58 | 4.91 | 33.08 | 132.75 | 220.43 | 312.19 | 367.87 | 511.23 | 554.92 | 588.44 | 373.28 | 343.37 | 170.10 | -8.45 | -117.45 | -29.91 | -42.08 | -45.46 |
Current Ratio |
4.1 | 4.6 | 4.7 | 4.3 | 4.7 | 3.5 | 3.5 | 3.4 | 4.8 | 6.0 | 5.4 | 5.2 | 6.5 | 6.0 | 7.3 | 6.1 | 7.2 | 6.0 | 7.5 | 6.3 | 6.3 | 6.3 | 6.3 | 3.0 | 3.0 | 3.0 | 3.0 | 2.8 | 2.8 | 2.8 | 2.8 | 1.6 | 1.6 | 1.6 | 1.6 | 1.3 | 1.3 | 1.3 | 1.3 | 3.0 | 3.0 | 3.0 | 3.0 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 1.6 | 1.6 | 1.6 | 1.6 |
DSO |
45.0 | 48.7 | 41.7 | - | 46.3 | 47.6 | 39.0 | - | 36.8 | 45.5 | 40.1 | - | 66.3 | 54.8 | 62.0 | - | 52.0 | 62.4 | 51.4 | - | 58.7 | 78.9 | 43.5 | - | 30.8 | 41.3 | 62.0 | - | 76.8 | 97.0 | 106.0 | - | 83.3 | 88.8 | 76.1 | - | 74.5 | 69.6 | 60.7 | - | 113.2 | 63.9 | 42.5 | - | 20.4 | 22.8 | 22.4 | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
122.8 | 117.7 | 121.0 | - | 196.7 | 190.1 | 179.4 | - | 129.5 | 139.2 | 158.2 | - | 225.8 | 293.0 | 377.1 | - | 364.7 | 449.6 | 396.4 | - | 540.2 | 709.7 | 345.8 | - | 183.2 | 248.2 | 261.9 | - | 220.3 | 317.3 | 223.5 | - | 160.2 | 179.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
38.7 | 33.4 | 31.9 | - | 51.9 | 77.4 | 67.9 | - | 32.6 | 31.8 | 42.0 | - | 60.7 | 72.4 | 92.0 | - | 65.2 | 73.4 | 36.5 | - | 43.1 | 56.6 | 60.8 | - | 68.6 | 92.9 | 106.2 | - | 98.8 | 142.3 | 150.4 | - | 207.2 | 232.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
167.8 | 166.4 | 162.7 | - | 243.0 | 237.7 | 218.4 | - | 166.3 | 184.8 | 198.3 | - | 292.2 | 347.7 | 439.1 | - | 416.7 | 512.0 | 447.8 | - | 598.9 | 788.6 | 389.2 | - | 214.0 | 289.5 | 323.9 | - | 297.2 | 414.3 | 329.5 | - | 243.4 | 268.6 | 76.1 | - | 74.5 | 69.6 | 60.7 | - | 113.2 | 63.9 | 42.5 | - | 20.4 | 22.8 | 22.4 | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
129.1 | 133.0 | 130.8 | - | 191.1 | 160.3 | 150.5 | - | 133.7 | 153.0 | 156.4 | - | 231.5 | 275.4 | 347.1 | - | 351.5 | 438.6 | 411.4 | - | 555.8 | 732.0 | 328.5 | - | 145.4 | 196.6 | 217.7 | - | 198.4 | 272.0 | 179.1 | - | 36.2 | 36.0 | 76.1 | - | 74.5 | 69.6 | 60.7 | - | 113.2 | 63.9 | 42.5 | - | 20.4 | 22.8 | 22.4 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Nephros, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AtriCure
ATRC
|
$ 28.22 | -2.32 % | $ 1.35 B | ||
|
Baxter International
BAX
|
$ 17.24 | 3.61 % | $ 8.84 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
BioLife Solutions
BLFS
|
$ 19.71 | 3.03 % | $ 908 M | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Ekso Bionics Holdings
EKSO
|
$ 8.73 | -3.64 % | $ 21.2 M | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
$ 77.31 | 3.54 % | $ 40.4 B | ||
|
Haemonetics Corporation
HAE
|
$ 59.53 | -0.05 % | $ 3 B | ||
|
Harvard Bioscience
HBIO
|
$ 5.55 | 2.78 % | $ 246 M | ||
|
The Cooper Companies
COO
|
$ 71.73 | 2.97 % | $ 14.3 B | ||
|
iRhythm Technologies
IRTC
|
$ 120.49 | 1.57 % | $ 3.86 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Repro Med Systems
KRMD
|
$ 4.19 | -1.18 % | $ 194 M | ||
|
Masimo Corporation
MASI
|
$ 178.3 | -0.24 % | $ 9.5 B | ||
|
Microbot Medical
MBOT
|
$ 2.35 | 2.62 % | $ 108 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
Milestone Scientific
MLSS
|
$ 0.27 | -4.66 % | $ 22.2 M | ||
|
Merit Medical Systems
MMSI
|
$ 69.24 | 2.73 % | $ 4.1 B | ||
|
electroCore
ECOR
|
$ 6.21 | -7.45 % | $ 52.7 K | ||
|
Envista Holdings Corporation
NVST
|
$ 26.66 | 5.42 % | $ 4.48 B | ||
|
Pro-Dex
PDEX
|
$ 48.97 | -1.63 % | $ 161 M | ||
|
Glaukos Corporation
GKOS
|
$ 118.62 | 3.09 % | $ 5.75 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M | ||
|
ICU Medical
ICUI
|
$ 123.92 | 3.41 % | $ 3.05 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.47 | 1.18 % | $ 196 M | ||
|
Intuitive Surgical
ISRG
|
$ 462.28 | 2.06 % | $ 165 B | ||
|
ResMed
RMD
|
$ 230.7 | 2.06 % | $ 33.7 B | ||
|
LeMaitre Vascular
LMAT
|
$ 112.41 | 1.89 % | $ 2.54 B | ||
|
Retractable Technologies
RVP
|
$ 0.68 | -4.59 % | $ 20.4 M | ||
|
Pulse Biosciences
PLSE
|
$ 19.06 | -4.51 % | $ 1.28 B | ||
|
STAAR Surgical Company
STAA
|
$ 20.88 | -1.0 % | $ 1.03 B | ||
|
STERIS plc
STE
|
$ 225.03 | 2.65 % | $ 22.2 B | ||
|
Stereotaxis
STXS
|
$ 1.93 | 4.32 % | $ 176 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Teleflex Incorporated
TFX
|
$ 119.03 | 3.05 % | $ 5.31 B | ||
|
Utah Medical Products
UTMD
|
$ 64.53 | 1.67 % | $ 209 M | ||
|
West Pharmaceutical Services
WST
|
$ 265.93 | 2.54 % | $ 19.2 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.99 | 4.08 % | $ 2.39 B | ||
|
AngioDynamics
ANGO
|
$ 10.17 | 4.85 % | $ 415 M | ||
|
Becton, Dickinson and Company
BDX
|
$ 157.09 | 1.37 % | $ 45.2 B | ||
|
OraSure Technologies
OSUR
|
$ 3.08 | 0.65 % | $ 226 M | ||
|
Repligen Corporation
RGEN
|
$ 119.77 | 3.89 % | $ 6.67 M |